Skip to content

Ultrasound Guided External Oblique and Rectus Abdominis Plane Block (EXORA) on Neuroendocrine Stress Response in Adults Undergoing Umbilical Hernia Surgery

The Effect of Ultrasound Guided External Oblique and Rectus Abdominis Plane Block (EXORA) on Neuroendocrine Stress Response in Adults Undergoing Umbilical Hernia Surgery: A Prospective Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07324863
Enrollment
100
Registered
2026-01-08
Start date
2025-08-01
Completion date
2026-09-01
Last updated
2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

External Oblique, Neuroendocrine Stress Response, Rectus Abdominis Plane Block, Ultrasound, Umbilical Hernia

Brief summary

This study aims to evaluate the efficacy of ultrasound-guided external oblique and rectus abdominis plane block on the neuroendocrine stress response and postoperative analgesia in adults undergoing umbilical hernia repair.

Detailed description

Umbilical hernias of the abdomen are defined as a non-inguinal, non-hiatal defect in the fascia of the abdominal wall. Surgical stress response refers to the physiologic response to surgery and the hormonal and metabolic changes that follow it. Fascial plane blocks are gaining attention for perioperative analgesia due to their efficacy and safety profiles. The external oblique and rectus abdominis plane (EXORA) block is an emerging technique that provides a sensory block to the anterolateral abdominal wall, potentially filling gaps left by other commonly used blocks, such as the quadratus lumborum (QLB) or erector spinae plane (ESP) blocks.

Interventions

OTHERGeneral anesthesia

Patients will receive general anesthesia only.

Patients will receive general anesthesia and an external oblique and rectus abdominis plane (EXORA) block with 0.25% bupivacaine.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Aged from 21 to 65 years. * Both sexes. * American Society of Anesthesiologists (ASA) Physical status I and Ⅱ. * Schedule for elective umbilical hernia surgery under general anesthesia.

Exclusion criteria

* ASA Ⅲ or Ⅳ. * Patients with metabolic abnormalities, e.g., diabetes mellitus. * Patients receiving corticosteroids. * History of allergies to local anesthetics. * Bleeding or coagulation disorders. * Anatomical abnormalities. * Psychiatric and neurological disorders. * Complicated hernial defect (obstructed). * Patient refusal.

Design outcomes

Primary

MeasureTime frameDescription
Neuroendocrine stress response24 hours postoperativelyNeuroendocrine stress response will be measured by blood glucose level in adults undergoing umbilical hernia repair.

Secondary

MeasureTime frameDescription
Serum cortisol level24 hours postoperativelySerum cortisol level will be measured.
Time of first rescue analgesia24 hours postoperativelyTime of first rescue analgesia will be recorded from the end of surgery till first dose of morphine administration.
Total intraoperative fentanyl consumptionIntraoperativelyRescue dose of intraoperative fentanyl given will be recorded.
Total morphine consumption24 hours postoperativelyIntravenous morphine (rescue analgesic) at a dosage of 3 mg will be administered when the Numerical Rating Scale (NRS) score will be ≥ 4. The total morphine consumption over a 24-hours period will be recorded for these individuals.
Degree of pain24 hours postoperativelyEach patient will be instructed in postoperative pain assessment using the Numerical Rating Scale (NRS), ranging from 0 to 10 (0 = no pain, 10 = the worst pain imaginable). NRS will be assessed at post-anesthesia care unit (PACU),1,2,4,6,12,24 hours postoperative

Countries

Egypt

Contacts

Primary ContactMayada H Sokeer, Master
mayada.hady@med.tanta.edu.eg00201095315597

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026